Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts

Journal of Nuclear Medicine

Volumn 39, Issue 5, 1998, Pages 842-849

  DeNardo, Sally J ^a   Kukis, David L ^b   Miers, Laird A ^b   Winthrop, Michelle D ^b   Kroger, Linda A ^b   Salako, Qansy ^b   Shen, Sui ^b   Lamborn, Kathleen R ^b   Gumerlock, Paul H ^b   Meares, Claude F ^b   DeNardo, Gerald L ^b  

^a Molecular Cancer Institute   (United States)

^b NONE

Author keywords

Apoptosis; Breast carcinoma; Radioimmunotherapy; Yttrium 90

Indexed keywords

ANTIBODY CONJUGATE; PROTEIN P53; UNCLASSIFIED DRUG; YTTRIUM DOTA PEPTIDE CHIMERIC L6 Y 90;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LETHAL DOSE 50; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; YTTRIUM; YTTRIUM RADIOISOTOPES;

EID: 0031956428     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. In: Ceriani RL, ed. Antigen and antibody molecular engineering in breast cancer diagnosis and treatment. New York: Plenum Press; 1994:203-211.
2. DeNardo SJ, Mirick GR, Kroger LA, et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73(suppl):1023-1032.
3. Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol 1996;24:1183-1190.
4. Wong JY, Williams LE, Yamauchi DM, et al. Initial experience evaluating yttrium-90-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res 1995;55(suppl):5929s-5934s.
5. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-1400.
6. Arano Y, Mukai T, Akizawa H, et al. Radiolabeled metabolites of proteins play a critical role in radioactivity elimination from the liver. Nucl Med Biol 1995;22:555-564.
7. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug Chem 1993;4:275-283.
8. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988;110:6266-6267.
9. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1989;30:473-479.
10. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxiciry studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73(suppl):1012-1022.
11. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111-and yttrium-90-DOTA-peptide in tumorbearing mice. J Nucl Med 1995;36:829-836.
12. Fell HP, Gayle MA, Yelton D, et al. Chimeric L6 anti-tumor antibody: genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992;267:15552-15558.
13. Liu AY, Robinson RR, Hellström KE, Murray ED, Chang CP, Hellström I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987;84:3439-3443.
14. Adams GP, DeNardo SJ, Amin A, et al. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric ChL6 antibody. Antibodies Immunoconj Radiopharm 1992;5:81-95.
15. Chi, SG, deVere White RW, Meyers FJ, Siders DB, Lee F, and Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86: 926-933.
16. DeNardo SJ, Gumerlock PH, Winthrop MD, et al. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis related mRNA expression. Cancer Res 1995;55:5837-5841.
17. Tewari M, Quan LT, O'Rourke D, et al. Yama/CPP32B, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-809.
18. 90Y radioimmunotherapy. Cancer Res 1994;54:5937-5946.
19. 111indium-DOTA chelates: a simple and efficient method. Bioconjug Chem 1994;5:101-104.
20. Penefsky HS. A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. Methods Enzymol 1979;56(part G):527-530.
21. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
22. Beaumier PL, Neuzil D, Yang H-M, et al. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 1986;27:824-828.
23. 111In-benzyl-EDTA-monoclonal antibody on hepatic uptake and processing in mice. Cancer Res 1989;49: 1707-1711.
24. Coursey BM, Calhoun JM, Cessna JT. Radioassay of yttrium-90 used in nuclear medicine. Nucl Med Biol 1993;20:693-699.
25. Buchegger F, Rojas A, Delaloye AB, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995;55: 83-89.
26. Hosono M, Endo K, Hosono MN, et al. Treatment of small-cell lung cancer xenografts with iodine-131-anti-neural cell adhesion molecule monoclonal antibody and evaluation of absorbed dose in tissue. J Nucl Med 1994;35:296-300.
27. Wilder RB, McGann JK, Sutherland WR, et al. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radial Oncol Biol Phys 1993;28:119-126.
28. Govindarajulu, Z. Statistical methods in bioassay. New York: Karger; 1988:5-6.
29. Dulbecco R, Ginsberg HS. The nature of viruses. In: Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, eds. Microbiology, 3rd Ed. Philadelphia: Harper and Row; 1980:883.
30. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971;12(suppl 5):5-23.
31. Hui TE, Fisher DR, Kuhn JA, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labded immunoconjugates. Cancer 1994;73(suppl):951-957.
32. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibodies Immunoconj Radiopharm 1990;3:213-233.
33. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3:71-79.
34. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35:152-156.
35. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley; 1973:120-123.
36. Agresti A. In: Categorical data analysis. New York: Wiley; 1990:283-287.
37. Casarett AP. Acute radiation effects in whole animals. In: Casarett AP, ed. Radiation biology. Edgewood Cliffs, NJ: Prentice-Hall; 1968:217-235.
38. Lewis JP, O'Grady LF, Green RA. Clinical and experimental: patterns of exogenous and endogenous hematopoietic repopulation following radiation injury. J Lab Clin Med 1977;89:229-239.
39. 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int J Radiat Oncol Biol Phys 1995;31:529-534.
40. Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4. Cancer Res 1991;51:1883-1890.
41. Marchese MJ, Zaider M, Hall EJ. Dose-rate effects in normal and malignant cells of human origin. Br J Radiol 1987;60:573-576.
42. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
43. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-4484.
44. Vaughan ATM, Anderson P, Dykes PW, Chapman CE, Bradwell AR. Limitations to the killing of tumors using radiolabelled antibodies. Br J Radiol 1987;60:567-578.
45. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JY. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 1993;20(suppl 2):601-610.
46. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
47. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
48. Fan S, el-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res 1994;54: 5824-5830.
49. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
50. Gu Y, Sarnecki C, Aldape RA, Livingston DJ, Su MSS. Cleavage of poly(ADP-ribose) polymerase by interleukin-1B converting enzyme and its homologs TX and Nedd-2. J Biol Chem 1995;270:18715-18718.
51. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
52. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.